NCI-2017-01380

OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

This research study is investigating a drug called MK-3475 (pembrolizumab) for triple-negative breast cancer (TNBC). Pembrolizumab is a drug that helps the immune system fight cancer cells. The study is designed to see how pembrolizumab affects the tumor microenvironment, which is the area around the tumor that contains cells and substances. Pembrolizumab is given before surgery (pre-operative) with or without intra-operative Radiation Therapy (IORT). Researchers hope to learn if pembrolizumab can alter the tumor microenvironment in a way that makes the cancer more susceptible to treatment.

Triple-Negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.

Intra-operative Radiation Therapy (IORT): Intraoperative radiation therapy (IORT) is a kind of radiation treatment that is performed during surgery. Radiation therapy (also called radiotherapy) is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors. This radiotherapy is a newer method that aims the radiation beam directly on the tissue with cancer.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT02977468

NCI-2017-01380

Clinical Trial Site: Columbia

To see all available clinical trials click here.